{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:19:45Z","timestamp":1788484785702,"version":"build-2803163510"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease arising from the interaction of environmental triggers with a genetically susceptible host. Among environmental factors, infection with Epstein\u2013Barr virus (EBV) has one of the strongest and most consistent epidemiological associations with SLE. Patients with SLE display higher EBV seropositivity rates, increased viral loads, and more frequent viral reactivations compared with healthy individuals. In genetically predisposed hosts, EBV can disturb immune homeostasis and contribute to the breakdown of self-tolerance, acting within a broader network of environmental influences that shape lupus pathogenesis. Despite this well-established association, the precise mechanisms linking EBV infection to lupus autoimmunity have remained incompletely understood. Recent single-cell RNA-sequencing revealed that EBV-infected B cells in SLE are transcriptionally distinct, with enhanced EBNA2-driven antigen presentation and ability to activate autoreactive CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells, which positions EBV as an active driver rather than a passive trigger of autoimmunity. These findings also highlight the interconnections between EBV-related mechanisms and dominant lupus pathways. These important new insights may have significant therapeutic implications, with a focus on B-cell targeted therapies that may suppress EBV reservoirs, while T-cell approaches, vaccines, and therapies disrupting EBV latency programs emerge as possible new strategies. This Mini Review summarizes established and emerging mechanistic evidence connecting EBV to SLE, with particular emphasis on recent data identifying EBV-infected B cells as potentialdrivers of lupus pathogenesis, and discusses the therapeutic implications of these findings.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1853891","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:43:08Z","timestamp":1780378988000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["How Epstein Barr virus shapes lupus autoimmunity: mechanistic insights and therapeutic perspectives"],"prefix":"10.3389","volume":"17","author":[{"given":"Rada","family":"Miskovic","sequence":"first","affiliation":[{"name":"Clinic of Allergy and Immunology, University Clinical Centre of Serbia","place":["Belgrade, Serbia"]},{"name":"Faculty of Medicine, University of Belgrade","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivica","family":"Jeremic","sequence":"additional","affiliation":[{"name":"Imedic Polyclinic","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijela","family":"Miljanovic","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andja","family":"Cirkovic","sequence":"additional","affiliation":[{"name":"Institute for Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Banko","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.JAUT.2018.11.001","article-title":"Systemic lupus erythematosus: Diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J Autoimmun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411292","article-title":"Association of IL10RA, IL10RB, and IL22RA polymorphisms\/haplotypes with susceptibility to and clinical manifestations of SLE","volume":"24","author":"Grk","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/370516","article-title":"Epstein-Barr virus and systemic lupus erythematosus","volume":"2012","author":"Draborg","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.587380","article-title":"Epstein-Barr virus and systemic autoimmune diseases","volume":"11","author":"Houen","year":"2021","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/V13020277","article-title":"Viral infections and systemic lupus erythematosus: New players in an old story","volume":"13","author":"Quaglia","year":"2021","journal-title":"Viruses"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2020.623944","article-title":"Epstein Barr virus and autoimmune responses in systemic lupus erythematosus","volume":"11","author":"Jog","year":"2021","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01167-9","article-title":"Epstein-Barr virus as a potentiator of autoimmune diseases","volume":"20","author":"Robinson","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ady0210","article-title":"Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus","volume":"17","author":"Younis","year":"2025","journal-title":"Sci Transl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(88)90028-1","article-title":"Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus","volume":"55","author":"Hammerschmidt","year":"1988","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/35095584","article-title":"Epstein-Barr virus: exploiting the immune system","volume":"1","author":"Thorley-Lawson","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/08916930802024772","article-title":"Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases","volume":"41","author":"Niller","year":"2008","journal-title":"Autoimmunity"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.172.2.1287","article-title":"Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus","volume":"172","author":"Kang","year":"2004","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/AR1181","article-title":"Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood","volume":"6","author":"Moon","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076156","article-title":"Epstein-Barr virus reactivation as a new predictor of achieving remission or lupus low disease activity state in patients with systemic lupus erythematosus with cutaneous involvement","volume":"24","author":"Miskovic","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10238-018-0535-0","article-title":"The risk of systemic lupus erythematosus associated with Epstein\u2013Barr virus infection: a systematic review and meta-analysis","volume":"19","author":"Li","year":"2019","journal-title":"Clin Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PPAT.1002328","article-title":"Exhausted cytotoxic control of Epstein-Barr virus in human lupus","volume":"7","author":"Larsen","year":"2011","journal-title":"PloS Pathog"},{"key":"B17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molimm.2024.05.003","article-title":"IFN-\u03b1 affects Th17\/Treg cell balance through c-Maf and associated with the progression of EBV- SLE","volume":"171","author":"Zhang","year":"2024","journal-title":"Mol Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/BOR.0000000000000289","article-title":"How compelling are the data for Epstein-Barr virus being a trigger for systemic lupus and other autoimmune diseases","volume":"28","author":"Draborg","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1307589","article-title":"Epstein-Barr virus infection as potential indicator of the occurrence and clinical presentation of systemic lupus erythematosus","volume":"14","author":"Banko","year":"2023","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11081958","article-title":"Markers of Epstein-Barr virus infection in association with the onset and poor control of rheumatoid arthritis: A prospective cohort study","volume":"11","author":"Miljanovic","year":"2023","journal-title":"Microorganisms"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2012.665944","article-title":"Epstein-Barr virus early antigen diffuse (EBV-EA\/D)-directed immunoglobulin A antibodies in systemic lupus erythematosus patients","volume":"41","author":"Draborg","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/SCIENCE.ABJ8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/J.JTAUTO.2021.100117","article-title":"Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus","volume":"4","author":"Wood","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2014.1578","article-title":"The expression of renal Epstein-Barr virus markers in patients with lupus nephritis","volume":"7","author":"Yu","year":"2014","journal-title":"Exp Ther Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215361","article-title":"Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals","volume":"78","author":"Jog","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2019.02619","article-title":"Anti-C1q antibodies as occurring in systemic lupus erythematosus could be induced by an Epstein-Barr virus-derived antigenic site","volume":"10","author":"Csorba","year":"2019","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0014488","article-title":"Antibodies elicited in response to EBNA-1 may cross-react with dsDNA","volume":"6","author":"Yadav","year":"2011","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.830993","article-title":"A high prevalence of anti-EBNA1 heteroantibodies in systemic lupus erythematosus (SLE) supports anti-EBNA1 as an origin for SLE autoantibodies","volume":"13","author":"Laurynenka","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1731285","article-title":"Aberrant B cell responses as drivers of autoantibody generation and epitope diversification in SLE pathogenesis","volume":"16","author":"Tariq","year":"2026","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2018.00187","article-title":"The possible effect of B-cell epitopes of Epstein-Barr virus early antigen, membrane antigen, latent membrane protein-1, and -2A on systemic lupus erythematosus","volume":"9","author":"Tu","year":"2018","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/S41588-018-0102-3","article-title":"Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity","volume":"50","author":"Harley","year":"2018","journal-title":"Nat Genet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.0904065","article-title":"Latent membrane protein 1, the EBV-encoded oncogenic mimic of CD40, accelerates autoimmunity in B6.Sle1 mice","volume":"185","author":"Peters","year":"2010","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317753069","article-title":"Epstein\u2013Barr virus infection and type I interferon signature in patients with systemic lupus erythematosus","volume":"27","author":"Han","year":"2018","journal-title":"Lupus"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.606936","article-title":"Epstein-Barr functional mimicry: Pathogenicity of oncogenic latent membrane protein-1 in systemic lupus erythematosus and autoimmunity","volume":"11","author":"Munroe","year":"2021","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147567","article-title":"Identifying patient-specific Epstein-Barr nuclear antigen-1 genetic variation and potential autoreactive targets relevant to multiple sclerosis pathogenesis","volume":"11","author":"Tschochner","year":"2016","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208957","article-title":"Epstein-Barr virus infection and variants of Epstein-Barr nuclear antigen-1 in synovial tissues of rheumatoid arthritis","volume":"13","author":"Masuoka","year":"2018","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002697","article-title":"Epstein-Barr virus infection of na\u00efve B cells in vitro frequently selects clones with mutated immunoglobulin genotypes: implications for virus biology","volume":"8","author":"Heath","year":"2012","journal-title":"PloS Pathog"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24904","article-title":"Association of clinical and serological parameters of systemic lupus erythematosus patients with Epstein-Barr virus antibody profile","volume":"90","author":"Chougule","year":"2018","journal-title":"J Med Virol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1146\/ANNUREV-IMMUNOL-101921-042422","article-title":"Systemic lupus erythematosus pathogenesis: Interferon and beyond","volume":"41","author":"Caielli","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2026.1710424","article-title":"Epstein Barr virus antigen-induced autoantibodies against complement C1q exacerbate renal disease in lupus-prone mice","volume":"17","author":"Tuncer","year":"2026","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11122825","article-title":"Epstein-Barr virus encephalitis: A review of case reports from the last 25 years","volume":"11","author":"Peuchmaur","year":"2023","journal-title":"Microorganisms"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/FMOLB.2021.816098","article-title":"Epstein-Barr virus and neurological diseases","volume":"8","author":"Zhang","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2516150","article-title":"Efficacy and safety of obinutuzumab in active systemic lupus erythematosus","author":"Furie","year":"2026","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.11.015","article-title":"B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment","volume":"85","author":"Agmon-Levin","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/ART.39856","article-title":"Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: Results from two phase III randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: Results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/AR3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00316","article-title":"B cell therapy in systemic lupus erythematosus: From rationale to clinical practice","volume":"7","author":"Parodis","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1101\/2025.10.19.682634","article-title":"Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cells","author":"Liu","year":"2025","journal-title":"bioRxiv Prepr Serv Biol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01252-4","article-title":"Targeting autoreactive B cells in SLE with anti-9G4 synthetic immune receptor T cells","volume":"26","author":"Ramba","year":"2026","journal-title":"Nat Rev Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103678","article-title":"The elimination of circulating Epstein-Barr virus infected B cells underlies anti-CD20 monoclonal antibody activity in multiple sclerosis: A hypothesis","volume":"59","author":"Berger","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1735301","article-title":"Signaling pathways in systemic lupus erythematosus and therapeutic implications","volume":"16","author":"Balogh","year":"2026","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10040109","article-title":"EBNA1: Oncogenic activity, immune evasion and biochemical functions provide targets for novel therapeutic strategies against Epstein-Barr virus- associated cancers","volume":"10","author":"Wilson","year":"2018","journal-title":"Cancers 2018 Vol 10"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0306482101","article-title":"Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide","volume":"101","author":"Farrell","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-3027-1","article-title":"Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo","volume":"17","author":"Lin","year":"2017","journal-title":"BMC Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200407000-00008","article-title":"The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease","volume":"27","author":"Bollard","year":"2004","journal-title":"J Immunother"},{"key":"B57","unstructured":"Study Details | NCT04645147 | Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection | ClinicalTrials.gov"},{"key":"B58","article-title":"Fomivirsen approved for CMV retinitis","volume":"4","author":"Roehr","year":"1998","journal-title":"J Int Assoc Physicians AIDS Care"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1853891\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:43:09Z","timestamp":1780378989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1853891\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2026.1853891"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1853891","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"article-number":"1853891"}}